Clinical trials: Bronchiectasis
Non-cystic Fibrosis Bronchiectasis, Chronic Mucus Hypersecretion
Simeox Therapy at Home Versus Standard of Care in NCFB Patients With CMH
This pilot RCT will assess benefits of Simeox technology on lung function, respiratory symptoms, health-related quality of life, subjective efficiency, device adherence at home, Patient satisfaction, tolerance, safety, and…
- Trial name
- NCT06237348
- Testing
- Simeox, Control
- Where
- 2 sites in Poland
- Volunteers
- 50 people
- Sponsor
- Physio-Assist
Non-Cystic Fibrosis Bronchiectasis
Nebulised RESP30X Nitric Oxide Formulations in NCFB Patients With Pseudomonas Aeruginosa (Pa)
A Phase 1/2a, Multi-Centre, Randomised, Open-label study to assess the safety, tolerability, PK, and efficacy of RESP30X in Adult NCFB participants with confirmed high-titre respiratory PPMs.
- Trial name
- NOPA (NCT06663176)
- Testing
- RESP302, RESP303
- Where
- Ukraine
- Volunteers
- 60 people
- Sponsor
- Thirty Respiratory Limited
Asthma Bronchiale, Bronchiectasis
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
- Conditions
- Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06820749
- Testing
- HSK31858
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Non-cystic Fibrosis Bronchiectasis
Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis
Bronchiectasis is a chronic lung disease of multiple aetiologies characterised by permanent dilatation of the calibre of a territory of the bronchial tree with impaired mucociliary clearance.
- Trial name
- Home-BRAC (NCT06487273)
- Testing
- SIMEOX, Remote Physiotherapy
- Where
- 57 sites in France, Germany and 4 more
- Volunteers
- 622 people
- Sponsor
- Physio-Assist
Non Cystic Fibrosis Bronchiectasis
Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)
This study (ARD-3150-1202, ORBIT-4) will evaluate the safety and efficacy of inhaled Pulmaquin (ciprofloxacin dispersion for inhalation) compared to inhaled placebo in subjects who have a confirmed diagnosis of non-cystic…
- Trial name
- NCT02104245
- Testing
- Ciprofloxacin dispersion for inhalation
- Where
- 95 sites in United States, Australia and 14 more
- Volunteers
- 304 people
- Sponsor
- Aradigm Corporation
Bronchiectasis Adult
Home Airway Clearance in Patients With Bronchiectasis (Home-Care Bronchiectasis)
Bronchiectasis is a chronic multiple etiologies pulmonary disease characterized by permanent dilatation of the caliber of the bronchial tree territory with an alteration of mucociliary clearance.
- Trial name
- NCT04742270
- Testing
- SIMEOX+ respiratory physiotherapy telecare
- Where
- 3 sites in France
- Volunteers
- 22 people
- Sponsor
- Physio-Assist
Bronchiectasis, Lower Respiratory Infection
Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.
To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa infection.
- Trial name
- NCT02096315
- Testing
- POL7080
- Where
- 4 sites in Spain, United Kingdom
- Volunteers
- 20 people
- Sponsor
- Polyphor Ltd.
Non-Cystic Fibrosis Bronchiectasis
Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis
The purpose of the study is to evaluate if INS1007 can reduce pulmonary exacerbations over a 24-week treatment period in participants with non-cystic fibrosis bronchiectasis.
- Trial name
- NCT03218917
- Testing
- Brensocatib 10 mg, Brensocatib 25 mg
- Where
- 108 sites in United States, Australia and 12 more
- Volunteers
- 256 people
- Sponsor
- Insmed Incorporated
Non-cystic Fibrosis Bronchiectasis
A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation
This study is open to adults with non-cystic fibrosis bronchiectasis. The main purpose of this study is to find out how a medicine called BI 1323495 is tolerated by people with non-cystic bronchiectasis.
- Trial name
- NCT04656275
- Testing
- BI 1323495
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- Boehringer Ingelheim
Bronchiectasis, Lung Disease
Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis
The purpose of this study is to investigate the effect of AZD5069 in patients with bronchiectasis.
- Conditions
- Bronchiectasis, Lung Disease, Respiratory Diseases
- Trial name
- STRATUS (NCT01255592)
- Testing
- AZD5069
- Where
- 15 sites in Czechia, Poland and 1 more
- Volunteers
- 83 people
- Sponsor
- AstraZeneca
Noncystic Fibrosis Bronchiectasis (NCFB)
Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)
This study is a prospective, multicenter, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and exploratory efficacy of nebulized CSL787 after…
- Trial name
- NCT04643587
- Testing
- CSL787
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- CSL Behring
Bronchiectasis
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).
- Trial name
- NCT06872892
- Testing
- BI 1291583
- Where
- 478 sites in United States, Argentina and 44 more
- Volunteers
- 1,755 people
- Sponsor
- Boehringer Ingelheim
Acute Exacerbations of Bronchiectasis
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
This is a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of inhaled H057 in the treatment of acute exacerbations of bronchiectasis.
- Trial name
- NCT06958861
- Testing
- Low-dose H057+standard-of-care, High-dose H057+standard-of-care
- Where
- 19 sites in China
- Volunteers
- 180 people
- Sponsor
- Shanghai Huilun Pharmaceutical Co., Ltd.
Asthma, Respiratory Candidiasis
The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases
This study tests the effects of an experimental drug PC945 in people with asthma or other chronic respiratory diseases whose lungs are infected by Aspergillus fungi and Candida yeasts.
- Conditions
- Asthma, Respiratory Candidiasis, Respiratory Aspergillosis, COPD
- Trial name
- NCT03745196
- Testing
- PC945
- Where
- 4 sites in United Kingdom
- Volunteers
- 13 people
- Sponsor
- Pulmocide Ltd
Bronchiectasis
Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.
This is a study to determine the safety and tolerability of 28 days of daily dosing of two doses (280 mg and 560 mg) of Arikayce™ versus placebo in patients who have bronchiectasis and chronic infection due to Pseudomonas…
- Trial name
- NCT00775138
- Testing
- 280 mg Arikayce™, 560 mg Arikayce™
- Where
- 18 sites in United States, Bulgaria and 7 more
- Volunteers
- 64 people
- Sponsor
- Insmed Incorporated
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Non-cystic Fibrosis Bronchiectasis
Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection
The purpose of this study was to support the selection of a safe and tolerable tobramycin inhalation powder (TIP) dose, and regimen that exhibits effective bacterial reduction of P.
- Trial name
- iBEST-1 (NCT02712983)
- Testing
- TIP
- Where
- 34 sites in Belgium, France and 4 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Primary Ciliary Dyskinesia
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
The goal of this observational study is to characterize clinical measures and biomarkers of airway disease in adults with primary ciliary dyskinesia (PCD) and in a group of healthy volunteers (HV) to establish normative values.
- Trial name
- NCT05685186
- Testing
- Spirometry, Multiple Breath Washout (MBW), Mucociliary Clearance (MCC)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- ReCode Therapeutics
Bronchiectasis Adult
Real Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS)
The purpose of this study is to collect data to assess the use of the LibAirty™ System for improving bronchiectasis symptoms and healthcare resource utilization when it is used at home.
- Trial name
- NCT07135284
- Testing
- Airway clearance system
- Where
- 3 sites in United States
- Volunteers
- 200 people
- Sponsor
- Synchrony-Medical, Ltd
Non-cystic Fibrosis Bronchiectasis
A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in non-cystic fibrosis bronchiectasis (NCFBE) participants.
- Trial name
- NCT06660992
- Testing
- HSK31858, tablet
- Where
- 2 sites in China
- Volunteers
- 669 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.